T1	Participants 52 120	type 2 diabetic patients with late failure of sulphonylurea therapy.
T2	Participants 229 350	patients with type 2 diabetes receiving exogenous insulin due to secondary failure of maximum dose sulphonylurea therapy.
T3	Participants 444 666	48 type 2 diabetic patients with late-term failure following at least 3 years of sulphonylurea therapy requiring additional insulin therapy to determine the impact of acarbose on glycaemic control and insulin requirements.
T4	Participants 1941 1966	type 2 diabetic patients.
